Lantern Pharma Launches withZeta.ai Platform for Rare Cancer Drug Discovery

Lantern Pharma Inc. (NASDAQ: LTRN) announced the commercial launch of withZeta.ai, its multi-agentic AI co-scientist platform for rare cancer drug discovery. Subscriptions are now available across academic and commercial tiers, creating a new non-dilutive revenue stream for the company. The platform, built from Lantern's RADR oncology-focused AI technologies, will be showcased at a private investor event at Nasdaq MarketSite in New York on April 16, 2026, and demonstrated publicly at the AACR Annual Meeting in San Diego from April 17–22.

The launch represents a significant strategic expansion for Lantern Pharma beyond its core clinical-stage precision oncology business. By making withZeta.ai commercially available as a subscription-based research platform, the company is opening access to the global biomedical and drug development community. This move transforms Lantern's proprietary AI technology from an internal research tool into a marketable product that can generate recurring revenue while potentially accelerating rare cancer research worldwide.

withZeta.ai is designed to address the specific challenges of rare cancer drug development, where traditional research approaches often face limitations due to small patient populations and limited economic incentives. The platform functions as an AI co-scientist that can investigate, reason, and synthesize across scientific evidence, potentially reducing the time and cost associated with drug discovery. According to company information, the platform is purpose-built for the biology, economics, and urgency of rare cancer drug development and is accessible to researchers anywhere.

The commercial availability of withZeta.ai comes as Lantern Pharma continues to advance its clinical pipeline, which includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog). LP-300 is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment, while LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.

The platform launch creates a diversified business model for Lantern Pharma, combining traditional drug development with technology commercialization. This approach could provide more stable revenue streams while the company's drug candidates progress through clinical trials. The subscription model allows academic and commercial researchers to access advanced AI capabilities without the substantial upfront investment typically required for such technology infrastructure. More information about the platform is available at https://withzeta.ai.

For investors and the broader oncology research community, the launch represents both a business milestone and a potential acceleration in rare cancer research. By making AI-driven drug discovery tools more widely available, Lantern Pharma could help address the significant unmet medical needs in rare cancers while establishing itself as a technology provider in the growing AI-enabled drug discovery market. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.